Fig. 6
From: Neuromodulation by nanozymes and ultrasound during Alzheimer’s disease management
A Half-life analysis of C-dot SOD nanozymes in plasma (n = 3 mice). B ex vivo fluorescence imaging analyses of the accumulations of C-dot SOD nanozymes (labeled with Cy5.5) in the brains of sham (24 h post-injection) and MCAO mice (2, 6, and 24 h post-injection), and corresponding brain sections (n = 3 mice). C The cerebral infarcted area analyses of MCAO mice treated with different dosages of C-dot SOD nanozymes for 24 h (n = 3 mice). D Representative 2,3,5- triphenyltetrazolium chloride-stained brain sections and E quantification of cerebral infarct areas of MCAO mice treated with different C-dot nanozymes (n = 3 mice). F Neurological score analyses of the MCAO mice treated with different C-dot nanozymes for 24 h (n = 5 mice). G Representative images of TUNEL staining in the brain sections (n = 3 mice, scale bar = 25 μm), H Malondialdehyde (MDA) assay in the brain homogenate, and ELISA assay of inflammatory factors (I) TNF-α, J IL-1β and (K) IL-6 of the infarcted brain of MCAO mice treated by different C-dot nanozymes (n = 3 mice). P values are determined with one-way ANOVA Tukey’s multiple comparisons test. Reproduced with permission copyright 2023, Nature communication [24]